Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
‘Revolutionary’: James Island pharmacist weighs in on newly approved medication
A James Island pharmacist is looking to the future of pain management thanks to the Food and Drug Administration approving a new treatment.
BioPharma Dive19h
Vertex’s new pain drug gets first coverage nod from major insurer
Optum, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in an ...
Vertex’s non-opioid pain drug gets some UnitedHealth coverage
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Vertex non-opioid pain drug picked up by UnitedHealth
Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...
Vertex Pharma drops as UnitedHealth offers Tier 3 coverage for new pain medicine
Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...
Investing.com India1d
UnitedHealth includes Vertex’s non-opioid painkiller in coverage, but at a higher cost - Bloomberg
Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...
BioPharma Dive1d
Tris to ask for approval of dual-acting pain drug
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Cannabis-like synthetic compound delivers pain relief without addictive high, study finds
U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...
Investing Snacks2d
Vertex’s Journavx Poised for Big Outpatient Market Win
Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...
2 Minute Medicine3d
Vertex: non-opioid pain reliever Journavx shows success in post operative pain control
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...